Get the Stockscreener App
41.51
0.26%
-0.05
Mirum Pharmaceuticals Inc stock is traded at $41.51, with a volume of 78,848.
It is down -0.26% in the last 24 hours and down -10.32% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$41.56
Open:
$41.18
24h Volume:
78,848
Relative Volume:
0.23
Market Cap:
$1.98B
Revenue:
$264.38M
Net Income/Loss:
$-109.16M
P/E Ratio:
-9.6629
EPS:
-4.2958
Net Cash Flow:
$-39.22M
1W Performance:
-0.67%
1M Performance:
-10.32%
6M Performance:
+21.23%
1Y Performance:
+40.41%
1-Day Range:
$40.93
$41.97
1-Week Range:
$40.93
$42.47
52-Week Range:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
41.51 | 1.98B | 264.38M | -109.16M | -39.22M | -2.3395 |
|
VRTX
Vertex Pharmaceuticals Inc
|
400.18 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.57 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.12 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.51 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.33 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
(MIRM) Trading Advice - Stock Traders Daily
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To Profitability - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Geode Capital Management LLC - MarketBeat
Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential (NASDAQ:MIRM) - Seeking Alpha
State Street Corp Buys 297,511 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Wellington Management Group LLP Has $4.77 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLC - MarketBeat
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea - Marketscreener.com
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - MarketBeat
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 - BioSpace
Frazier Life Sciences Management L.P. Purchases 75,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues - Simply Wall St
Charles Schwab Investment Management Inc. Acquires 17,149 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Janus Henderson Group PLC - MarketBeat
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - MSN
Erste Asset Management GmbH Buys Shares of 260,000 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Intech Investment Management LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Eventide Asset Management LLC Sells 1,119,457 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Loomis Sayles & Co. L P Buys New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 21,526 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
(MIRM) Technical Data - Stock Traders Daily
Mirum Pharmaceuticals success with study of drug for chronic liver disease - OutSourcing-Pharma.com
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Phocas Financial Corp. Cuts Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.73 - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Decreased by First Turn Management LLC - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 4.6% After Insider Selling - MarketBeat
Cantor Fitzgerald Analysts Raise Earnings Estimates for MIRM - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting - Business Wire
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Nov 14 '24 |
Sale |
47.10 |
2,500 |
117,752 |
2,426 |
| Heron Patrick J | Director |
Sep 18 '24 |
Buy |
37.40 |
115 |
4,301 |
162,308 |
| Heron Patrick J | Director |
Sep 06 '24 |
Buy |
41.58 |
230 |
9,563 |
162,193 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jul 23 '24 |
Option Exercise |
2.94 |
34,013 |
99,862 |
126,783 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jul 02 '24 |
Sale |
34.00 |
375 |
12,750 |
2,426 |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER |
Jun 24 '24 |
Option Exercise |
2.94 |
30,559 |
89,721 |
57,965 |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER |
Jun 24 '24 |
Sale |
34.00 |
30,559 |
1,039,006 |
27,406 |
| Ramasastry Saira | Director |
Jun 05 '24 |
Option Exercise |
14.12 |
5,000 |
70,600 |
5,000 |
| Ramasastry Saira | Director |
Jun 05 '24 |
Sale |
25.68 |
5,000 |
128,400 |
0 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Mar 27 '24 |
Buy |
24.80 |
2,000 |
49,600 |
14,000 |
1.03%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):